Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.23.1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2022
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers         $ 2,750      
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation     $ 7,300          
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period 180 days              
Number of performance obligations | item 1              
Cash payment received     17,700       $ 37,000  
Revenue from contracts with customers   $ 35,000 $ 25,000 $ 0 $ 0 $ 10,000 $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 480,000     410,000        
Royalty payment period 10 years              
Contract assets       0       $ 0
Contract liabilities       0       0
Capitalized contract costs       $ 0       $ 0